Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

Name: Kaimen Rigor review — Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Item: Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.
Rating: 100
Author: Alpha1

Cortés J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Chiu JWY, Pedrini JL, Li W, Yonemori K, Bianchini G, Loi S, Borges GS, Wang X, Bachelot T, Nakatani S, Ashfaque S, Liang Z, Egorov A, Hamilton E

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 4.75★ (Strong), 0 critical, 5 high issues for “Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Read alongside

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03021-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f8dcff95-c9fa-483b-8586-0d4cd5d73254" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f8dcff95-c9fa-483b-8586-0d4cd5d73254/badge" alt="Kaimen Rigor review — 4.75★ (Strong), 0 critical, 5 high issues for “Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

006502842b73bd207073c7a94dc987ecd29d9a43a16abf2ea24006ae393b6f56

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

Paper source

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 16, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

4.75 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

01ArithmeticNone found 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a rigorously conducted and transparently reported phase 3 randomized controlled trial with strong scientific premise, detailed methods, and appropriate statistical analysis. Minor reporting gaps exist (explicit power analysis, outlier handling, exact p-values for exploratory analyses, and statistical assumption verification), but none undermine the validity of the findings. The paper is well-suited for publication and the post-publication robustness is high.

Both reviewers independently scored all eight dimensions and agreed on the status of each, with only minor sub-criterion differences in study design and statistical analysis. The study type is interventional (phase 3 RCT). Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification recomputed 5 reported tests/effect estimates, all consistent; coverage is limited to tests with test statistics/df or effect estimates with CIs, so other statistics remain unverified. The citation check found 1 reference not found in registry (potential fabrication signal), which is addressed in the action items.

Numerical inconsistencies

None found

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Checked — nothing surfaced.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

1 finding · worst low

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The paper cites numerous prior studies establishing HER2 as a therapeutic target and the development of T-DXd and T-DM1. It acknowledges strengths and weaknesses of prior work, including the EMILIA trial and CLEOPATRA trial. The rationale for comparing T-DXd to T-DM1 is logically presented based on their differing mechanisms and drug-to-antibody ratios. Limitations of prior analyses (e.g., median OS not reached) are explicitly addressed as motivation for this updated analysis.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on HER2-positive breast cancer and the development of T-DXd, and clearly links this to the study's objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“Human epidermal growth factor receptor 2 (HER2)-positive breast cancer is characterized by amplification of the HER2 (ERBB2) gene and/or overexpression of the HER2 protein, which stimulates cell proliferation, survival, differentiation, angiogenesis and invasion.”

“We report on an exploratory analysis of DESTINY-Breast03 (data cutoff, 20 November 2023), with updated efficacy, including median OS, and safety data with longer follow-up.”

IntroductionFind in source

“Longer follow-up is needed to determine a more precise estimate of the median OS in the T-DXd group due to the number of patients censored; more mature data are expected at the next data cutoff as the study continues.”

Discussion ¶8Find in source

PASSReviewer 2· 95% conf

The scientific premise is well-established with extensive prior work cited, a clear rationale linking HER2 targeting to the study objectives, and limitations of prior research acknowledged.

Evidence

“The discovery of HER2 alterations led to the development of treatments that specifically target HER2, resulting in improved prognosis for patients with this subtype of breast cancer”

Main, paragraphs 1-3Find in source

“T-DXd has a high, homogeneous drug-to-antibody ratio of approximately 8, while T-DM1 has a drug-to-antibody ratio of approximately 3.5”

Main, paragraph 3Find in source

“However, median OS was not reached in either treatment group at the primary analysis or the second OS interim analysis”

Main, paragraph 4Find in source

The study is an open-label, multicenter, phase 3 trial with balanced block randomization and stratification factors. The randomization method and unit are described. Blinding of patients and investigators was not possible, but tumor assessments were performed by BICR, which is an acceptable alternative. The sample size was pre-specified (approximately 500 patients), and inclusion/exclusion criteria are detailed. The analysis populations (full analysis set and safety analysis set) are defined, and the handling of missing data is implicit in the survival analysis methods.

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified endpoints, though blinding was not possible due to the nature of the treatments.

Evidence

“Randomization of patients involved balanced block randomization with a 1:1 allocation ratio for T-DXd and T-DM1.”

MethodsFind in source

paraphrase[Methods, Trial design]

“Due to distinct administration protocols and adverse event profiles of the treatments, blinding of patients and investigators was not possible. However, tumor assessments were performed by BICR, which were previously reported.”

“The study aimed to enroll approximately 500 patients, with random assignment determined using EAST software version 6.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The study design is rigorous for a phase 3 clinical trial, with clear randomization, stratification, and pre-specified endpoints. Blinding was not possible due to distinct administration protocols, but BICR was used for the primary endpoint.

Evidence

“Randomization of patients involved balanced block randomization with a 1:1 allocation ratio for T-DXd and T-DM1.”

MethodsFind in source

“The study aimed to enroll approximately 500 patients, with random assignment determined using EAST software version 6.4.”

Statistical analysisFind in source

Sex is reported (99.6% female in both groups). Age is reported with median and range. Demographics including race, ethnicity, region, ECOG PS, HER2 IHC status, hormone receptor status, and CNS/liver/lung metastases are all detailed in Table 1. Species/strain/source and housing conditions are not applicable for a human trial. Sex justification is not applicable as both sexes are enrolled.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are thoroughly reported, including sex, age, race, and disease-related variables.

Evidence

“Female | 260 (99.6) | 262 (99.6) | | Male | 1 (0.4) | 1 (0.4)”

Table 1Find in source

“The median age was 54.3 years (range, 27.9–83.1 years) in the T-DXd group and 54.2 years (range, 20.2–83.0 years) in the T-DM1 group.”

ResultsFind in source

“Race, n (%) | | White | 71 (27.2) | 72 (27.4) | | Black or African American | 10 (3.8) | 9 (3.4) | | Asian | 152 (58.2) | 162 (61.6)”

Table 1Find in source

PASSReviewer 2· 95% conf

Biological variables are well-reported for a human clinical trial, including sex, age, race, ethnicity, HER2 status, hormone receptor status, and baseline disease characteristics.

Evidence

paraphrase[Table 1]

“Sex, n (%) | Female | 260 (99.6) | 262 (99.6) | | Male | 1 (0.4) | 1 (0.4)”

“The median age was 54.3 years (range, 27.9–83.1 years) in the T-DXd group and 54.2 years (range, 20.2–83.0 years) in the T-DM1 group.”

Results ¶1Find in source

paraphrase[Table 1]

“HER2 IHC status, n (%) | IHC 3+ | 234 (89.7) | 232 (88.2)”

The trial protocol was approved by ethical bodies or institutional review boards at each site, and all patients provided written informed consent. The study was conducted in accordance with the Declaration of Helsinki and ICH-GCP. This meets the criteria for adequate ethics reporting.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented, with a named ethics body and compliance with the Declaration of Helsinki and GCP.

Evidence

“Before initiation of the study, the trial protocol was approved by the ethical bodies or institutional review boards at each site.”

MethodsFind in source

“All participating patients provided their informed consent in writing before enrollment.”

MethodsFind in source

“The study was conducted in accordance with the standards set by the Declaration of Helsinki, the International Conference on Harmonization Guideline for Good Clinical Practice, any local regulations and the study protocol.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are adequately reported: the protocol was approved by ethical bodies/IRBs at each site, informed consent was obtained, and compliance with the Declaration of Helsinki and ICH-GCP is stated.

Evidence

“Before initiation of the study, the trial protocol was approved by the ethical bodies or institutional review boards at each site.”

MethodsFind in source

“All participating patients provided their informed consent in writing before enrollment.”

MethodsFind in source

The study uses two antibody-drug conjugates, T-DXd and T-DM1, which are identified by name and dose (5.4 mg/kg and 3.6 mg/kg). The manufacturer is implied (Daiichi Sankyo). Statistical software (SAS, R) is identified. No other biological or chemical resources are used, so other sub-criteria are not applicable.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (T-DXd and T-DM1) are identified with doses and regimens, and statistical software is named.

Evidence

“Patients with advanced HER2-positive metastatic breast cancer previously treated with taxane and trastuzumab were randomized to T-DXd (5.4 mg per kg (261 patients)) or T-DM1 (3.6 mg per kg (263 patients)).”

AbstractFind in source

“Statistical analysis used SAS version 9.3 or later and R 4.2.0 for the RPSFTM.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Key resources are adequately identified for a clinical trial: the investigational products (T-DXd and T-DM1) are named with doses and regimens, and statistical software is identified. Antibodies, cell lines, and organisms are not applicable.

Evidence

AbstractFind in source

“Statistical analysis used SAS version 9.3 or later and R 4.2.0 for the RPSFTM.”

Statistical analysisFind in source

The paper reports hazard ratios with 95% CIs for PFS, OS, and PFS2, which is the standard for clinical trials. The statistical tests are named (stratified log-rank test, Cox proportional hazards model, Cochran-Mantel-Haenszel test). Exact p-values are not reported for the updated analyses, but this is acceptable as the analyses are exploratory and effect estimates with CIs are provided. Software is identified. Data presentation includes Kaplan-Meier curves and tables with per-group n. Mathematical plausibility checks were not performed due to the nature of the data (survival analysis).

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are not the primary focus.

Evidence

“Analysis of PFS and OS between treatment groups employed a stratified log-rank test, considering randomization factors.”

Statistical analysisFind in source

“median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56–0.94) with T-DXd versus T-DM1, respectively.”

AbstractFind in source

“Statistical analysis used SAS version 9.3 or later and R 4.2.0 for the RPSFTM.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Statistical analysis is rigorous and well-reported. Tests are named, effect sizes with confidence intervals are provided, software is identified, and data presentation is appropriate for a clinical trial. Exact p-values are not reported for all analyses (some are reported as thresholds), but this is acceptable given the hierarchical testing and estimation-focused reporting.

Evidence

“Analysis of PFS and OS between treatment groups employed a stratified log-rank test, considering randomization factors.”

Statistical analysisFind in source

“median PFS by investigator assessment was 29.0 versus 7.2 months (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.24–0.38)”

AbstractFind in source

“median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56–0.94) with T-DXd versus T-DM1, respectively.”

AbstractFind in source

The data availability statement provides a concrete route for accessing anonymized individual participant data through the Vivli platform, with a link to the specific member page. This meets the criteria for adequate data availability. Since the data are patient-level and identifiable, repository deposit and accession numbers are not applicable. No custom code is mentioned, so code sharing is not applicable.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is clearly stated with a concrete access route via Vivli, and no bespoke code is mentioned.

Evidence

paraphrase[Data availability]

“Anonymized individual participant data on completed studies and applicable supporting clinical study documents may be available upon request at https://vivli.org/.”

PASSReviewer 2· 90% conf

Data availability is adequately addressed: a data availability statement is present, and a concrete route for accessing anonymized individual patient data via the Vivli platform is provided. Code sharing is not applicable as no custom code is described beyond standard statistical software.

Evidence

paraphrase[Data availability]

“Anonymized individual participant data on completed studies and applicable supporting clinical study documents may be available upon request at https://vivli.org/.”

paraphrase[Data availability]

“Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/.”

The trial is registered (NCT03529110). Methods are detailed enough for replication. The paper discusses limitations, including the exploratory nature of the analysis and the lack of BICR for updated endpoints. Conclusions are proportional to the evidence, with appropriate caveats about cross-trial comparisons. Funding and competing interests are disclosed.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Abstract]

“ClinicalTrials.gov registration: NCT03529110 (https://classic.clinicaltrials.gov/ct2/show/NCT03529110).”

paraphrase[Discussion, last paragraph]

“Potential limitations of the DESTINY-Breast03 trial have been published. In the current analysis, PFS, ORR and DoR were assessed by the investigators, not by BICR; consequently, no formal statistical comparisons were made.”

“This study was funded by Daiichi Sankyo and AstraZeneca.”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

Reporting transparency is high: methods are detailed, the trial is registered, limitations are discussed, conclusions are proportional, and funding/COI are disclosed. A reporting guideline is referenced (Nature Portfolio reporting summary).

Evidence

“ClinicalTrials.gov registration: NCT03529110”

AbstractFind in source

“Potential limitations of the DESTINY-Breast03 trial have been published”

Discussion ¶7Find in source

“This study was funded by Daiichi Sankyo and AstraZeneca.”

AcknowledgementsFind in source

Registered (3 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 25 references by DOI: 24 verified — 1 DOI unresolved.

2 data/code links checked; 2 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported; an informed reader should weigh the minor reporting gaps (explicit power analysis, outlier handling, exact p-values for exploratory analyses, and statistical assumption verification) as limitations but not validity threats. The one reference not found in the registry should be verified or corrected, as it may be a fabrication signal. No erratum is warranted for the statistical results, as all recomputed tests were consistent.

1.
HIGHreporting
Verify or correct the reference 'ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen' (DOI 10.1016/s1470-2045(19) — incomplete DOI) that was not found in any registry; if it cannot be verified, remove or replace it.
A reference that cannot be located in any registry is a potential fabrication signal and must be resolved before publication.
2.
HIGHreporting
Add an explicit a priori power analysis to the Methods (Statistical analysis) section, stating the assumed effect size, alpha, and power that justified the target enrollment of ~500 patients.
Reviewer 2 flagged the absence of an explicit power calculation as a reporting gap; providing it strengthens the study design reporting.
3.
HIGHstatistics
Report exact p-values for the updated exploratory analyses (e.g., OS HR) in the Abstract and Results, or state that p-values are intentionally omitted for exploratory analyses.
Both reviewers noted that exact p-values are not reported for the current exploratory analysis; adding them would facilitate interpretation.
4.
HIGHstatistics
Add a statement in the Methods (Statistical analysis) on how outliers were handled, even if none were identified or standard methods were used.
Reviewer 2 flagged outlier handling as not reported; a brief statement would close this reporting gap.
5.
HIGHstatistics
Explicitly state that assumptions of the statistical models (e.g., proportional hazards for the Cox model) were verified, or note that standard methods were used and assumptions are considered met.
Reviewer 2 flagged assumptions verification as inadequate; adding this statement improves transparency.
6.
MEDIUMreporting
Clarify the reporting guideline used (e.g., CONSORT) in the Methods or reporting summary, rather than only referencing the Nature Portfolio reporting summary.
Reviewer 1 suggested clarifying the reporting guideline to enhance transparency.
7.
MEDIUMstatistics
Provide more detail on the RPSFTM sensitivity analysis in the Methods, including assumptions and potential biases.
Reviewer 1 suggested this to aid reproducibility.
8.
MEDIUMreporting
Provide a more detailed description of the randomization algorithm (e.g., block sizes) in the Methods (Trial design).
Reviewer 2 suggested this to strengthen the design reporting.
9.
MEDIUMreporting
Add a statement on whether any data were excluded from analysis and the reasons for exclusion, beyond the pre-specified criteria.
Reviewer 2 suggested this to enhance transparency.
10.
MEDIUMstatistics
Consider adding a supplementary table with exact p-values for all secondary and exploratory endpoints.
Reviewer 2 suggested this to enhance transparency.
11.
LOWcopyedit
Fix the typo 'sequalae' to 'sequelae' in the Discussion.
Copyedit pass flagged this spelling error.
12.
LOWcopyedit
Add 'respectively' to the Abstract sentence 'median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56–0.94)' for clarity.
Copyedit pass flagged this as a minor clarity issue.
13.
LOWcopyedit
Clarify the Abstract sentence 'Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months)' by adding 'at the primary analysis' to avoid confusion with the current longer follow-up.
Copyedit pass flagged this as potentially misleading.
14.
LOWcopyedit
Ensure consistent formatting of HRs across tables (e.g., Table 2) and clarify that Table 3 uses the safety analysis set (n=257 for T-DXd) in the table title.
Copyedit pass flagged formatting and consistency issues in tables.

Full text (55,293 chars)Analyzed: Aug 16, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.

Read full text (PMC)

DOI

10.1038/s41591-024-03021-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f8dcff95-c9fa-483b-8586-0d4cd5d73254" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f8dcff95-c9fa-483b-8586-0d4cd5d73254/badge" alt="Kaimen Rigor review — 4.75★ (Strong), 0 critical, 5 high issues for “Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

006502842b73bd207073c7a94dc987ecd29d9a43a16abf2ea24006ae393b6f56

Verify via API

Issued Aug 16, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

4.75 / 5

Strong — minor issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsUnresolved reference−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Findings by category

01ArithmeticNone found 102OverreachOverstated conclusions 03AuthenticityNone found 04DisclosureNone found 105AvailabilityBroken references and links 06Copyedit5 minor suggestions

Numerical inconsistencies

None found

Checked — nothing surfaced.

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

1 finding · worst low

Conclusions only partially backed by the presented evidenceAssessed

5 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on HER2-positive breast cancer and the development of T-DXd, and clearly links this to the study's objectives.

Evidence

paraphrase[Introduction, paragraph 1]

“We report on an exploratory analysis of DESTINY-Breast03 (data cutoff, 20 November 2023), with updated efficacy, including median OS, and safety data with longer follow-up.”

IntroductionFind in source

Discussion ¶8Find in source

PASSReviewer 2· 95% conf

The scientific premise is well-established with extensive prior work cited, a clear rationale linking HER2 targeting to the study objectives, and limitations of prior research acknowledged.

Evidence

“The discovery of HER2 alterations led to the development of treatments that specifically target HER2, resulting in improved prognosis for patients with this subtype of breast cancer”

Main, paragraphs 1-3Find in source

“T-DXd has a high, homogeneous drug-to-antibody ratio of approximately 8, while T-DM1 has a drug-to-antibody ratio of approximately 3.5”

Main, paragraph 3Find in source

“However, median OS was not reached in either treatment group at the primary analysis or the second OS interim analysis”

Main, paragraph 4Find in source

Sub-criteria

controlsN/A

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, stratification, and pre-specified endpoints, though blinding was not possible due to the nature of the treatments.

Evidence

“Randomization of patients involved balanced block randomization with a 1:1 allocation ratio for T-DXd and T-DM1.”

MethodsFind in source

paraphrase[Methods, Trial design]

“The study aimed to enroll approximately 500 patients, with random assignment determined using EAST software version 6.4.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Evidence

“Randomization of patients involved balanced block randomization with a 1:1 allocation ratio for T-DXd and T-DM1.”

MethodsFind in source

“The study aimed to enroll approximately 500 patients, with random assignment determined using EAST software version 6.4.”

Statistical analysisFind in source

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and baseline characteristics are thoroughly reported, including sex, age, race, and disease-related variables.

Evidence

“Female | 260 (99.6) | 262 (99.6) | | Male | 1 (0.4) | 1 (0.4)”

Table 1Find in source

“The median age was 54.3 years (range, 27.9–83.1 years) in the T-DXd group and 54.2 years (range, 20.2–83.0 years) in the T-DM1 group.”

ResultsFind in source

“Race, n (%) | | White | 71 (27.2) | 72 (27.4) | | Black or African American | 10 (3.8) | 9 (3.4) | | Asian | 152 (58.2) | 162 (61.6)”

Table 1Find in source

PASSReviewer 2· 95% conf

Biological variables are well-reported for a human clinical trial, including sex, age, race, ethnicity, HER2 status, hormone receptor status, and baseline disease characteristics.

Evidence

paraphrase[Table 1]

“Sex, n (%) | Female | 260 (99.6) | 262 (99.6) | | Male | 1 (0.4) | 1 (0.4)”

“The median age was 54.3 years (range, 27.9–83.1 years) in the T-DXd group and 54.2 years (range, 20.2–83.0 years) in the T-DM1 group.”

Results ¶1Find in source

paraphrase[Table 1]

“HER2 IHC status, n (%) | IHC 3+ | 234 (89.7) | 232 (88.2)”

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approval and informed consent are clearly documented, with a named ethics body and compliance with the Declaration of Helsinki and GCP.

Evidence

“Before initiation of the study, the trial protocol was approved by the ethical bodies or institutional review boards at each site.”

MethodsFind in source

“All participating patients provided their informed consent in writing before enrollment.”

MethodsFind in source

PASSReviewer 2· 95% conf

Evidence

“Before initiation of the study, the trial protocol was approved by the ethical bodies or institutional review boards at each site.”

MethodsFind in source

“All participating patients provided their informed consent in writing before enrollment.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (T-DXd and T-DM1) are identified with doses and regimens, and statistical software is named.

Evidence

AbstractFind in source

“Statistical analysis used SAS version 9.3 or later and R 4.2.0 for the RPSFTM.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Evidence

AbstractFind in source

“Statistical analysis used SAS version 9.3 or later and R 4.2.0 for the RPSFTM.”

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesN/A

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with effect sizes and confidence intervals reported; p-values are not the primary focus.

Evidence

“Analysis of PFS and OS between treatment groups employed a stratified log-rank test, considering randomization factors.”

Statistical analysisFind in source

“median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56–0.94) with T-DXd versus T-DM1, respectively.”

AbstractFind in source

“Statistical analysis used SAS version 9.3 or later and R 4.2.0 for the RPSFTM.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

Evidence

“Analysis of PFS and OS between treatment groups employed a stratified log-rank test, considering randomization factors.”

Statistical analysisFind in source

“median PFS by investigator assessment was 29.0 versus 7.2 months (hazard ratio (HR), 0.30; 95% confidence interval (CI), 0.24–0.38)”

AbstractFind in source

“median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56–0.94) with T-DXd versus T-DM1, respectively.”

AbstractFind in source

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is clearly stated with a concrete access route via Vivli, and no bespoke code is mentioned.

Evidence

paraphrase[Data availability]

“Anonymized individual participant data on completed studies and applicable supporting clinical study documents may be available upon request at https://vivli.org/.”

PASSReviewer 2· 90% conf

Evidence

paraphrase[Data availability]

“Anonymized individual participant data on completed studies and applicable supporting clinical study documents may be available upon request at https://vivli.org/.”

paraphrase[Data availability]

“Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/.”

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper is transparent with trial registration, detailed methods, discussion of limitations, and proportional conclusions.

Evidence

paraphrase[Abstract]

“ClinicalTrials.gov registration: NCT03529110 (https://classic.clinicaltrials.gov/ct2/show/NCT03529110).”

paraphrase[Discussion, last paragraph]

“This study was funded by Daiichi Sankyo and AstraZeneca.”

AcknowledgementsFind in source

PASSReviewer 2· 90% conf

Evidence

“ClinicalTrials.gov registration: NCT03529110”

AbstractFind in source

“Potential limitations of the DESTINY-Breast03 trial have been published”

Discussion ¶7Find in source

“This study was funded by Daiichi Sankyo and AstraZeneca.”

AcknowledgementsFind in source

Registered (3 IDs: ClinicalTrials.gov). No reporting guideline cited.

Broken references and links

1 finding · worst low

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

Checked 25 references by DOI: 24 verified — 1 DOI unresolved.

2 data/code links checked; 2 live.

Copyediting

5 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 5 minor suggestions below.

5 copyedit issues flagged: mostly consistency, typo, clarity.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHreporting
Verify or correct the reference 'ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen' (DOI 10.1016/s1470-2045(19) — incomplete DOI) that was not found in any registry; if it cannot be verified, remove or replace it.
A reference that cannot be located in any registry is a potential fabrication signal and must be resolved before publication.
2.
HIGHreporting
Add an explicit a priori power analysis to the Methods (Statistical analysis) section, stating the assumed effect size, alpha, and power that justified the target enrollment of ~500 patients.
Reviewer 2 flagged the absence of an explicit power calculation as a reporting gap; providing it strengthens the study design reporting.
3.
HIGHstatistics
Report exact p-values for the updated exploratory analyses (e.g., OS HR) in the Abstract and Results, or state that p-values are intentionally omitted for exploratory analyses.
Both reviewers noted that exact p-values are not reported for the current exploratory analysis; adding them would facilitate interpretation.
4.
HIGHstatistics
Add a statement in the Methods (Statistical analysis) on how outliers were handled, even if none were identified or standard methods were used.
Reviewer 2 flagged outlier handling as not reported; a brief statement would close this reporting gap.
5.
HIGHstatistics
Explicitly state that assumptions of the statistical models (e.g., proportional hazards for the Cox model) were verified, or note that standard methods were used and assumptions are considered met.
Reviewer 2 flagged assumptions verification as inadequate; adding this statement improves transparency.
6.
MEDIUMreporting
Clarify the reporting guideline used (e.g., CONSORT) in the Methods or reporting summary, rather than only referencing the Nature Portfolio reporting summary.
Reviewer 1 suggested clarifying the reporting guideline to enhance transparency.
7.
MEDIUMstatistics
Provide more detail on the RPSFTM sensitivity analysis in the Methods, including assumptions and potential biases.
Reviewer 1 suggested this to aid reproducibility.
8.
MEDIUMreporting
Provide a more detailed description of the randomization algorithm (e.g., block sizes) in the Methods (Trial design).
Reviewer 2 suggested this to strengthen the design reporting.
9.
MEDIUMreporting
Add a statement on whether any data were excluded from analysis and the reasons for exclusion, beyond the pre-specified criteria.
Reviewer 2 suggested this to enhance transparency.
10.
MEDIUMstatistics
Consider adding a supplementary table with exact p-values for all secondary and exploratory endpoints.
Reviewer 2 suggested this to enhance transparency.
11.
LOWcopyedit
Fix the typo 'sequalae' to 'sequelae' in the Discussion.
Copyedit pass flagged this spelling error.
12.
LOWcopyedit
Add 'respectively' to the Abstract sentence 'median OS was 52.6 versus 42.7 months (HR, 0.73; 95% CI, 0.56–0.94)' for clarity.
Copyedit pass flagged this as a minor clarity issue.
13.
LOWcopyedit
Clarify the Abstract sentence 'Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months)' by adding 'at the primary analysis' to avoid confusion with the current longer follow-up.
Copyedit pass flagged this as potentially misleading.
14.
LOWcopyedit
Ensure consistent formatting of HRs across tables (e.g., Table 2) and clarify that Table 3 uses the safety analysis set (n=257 for T-DXd) in the table title.
Copyedit pass flagged formatting and consistency issues in tables.

Full text (55,293 chars)Analyzed: Aug 16, 2026